Stock Events

Stock Events

Biohaven 

$9.8
0
+$0.32+3.38% Monday 00:03

Statistics

Day High
9.8
Day Low
9.8
52W High
-
52W Low
-
Volume
4
Avg. Volume
-
Mkt Cap
1.47B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

8MayExpected
Q3 2025
Q4 2025
Next
-1.9
-1.55
-1.19
-0.84
Expected EPS
-0.839402
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2022
2023
2024
0Revenue
-1.69BNet Income

Analyst Ratings

$16.89Average Price Target
The highest estimate is 30.00.
From 9 ratings within the last 6 months. This is not an investment recommendation.
Buy
67%
Hold
33%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow BHVN.BOATS. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Lilly(Eli) &
LLY
Mkt Cap837.36B
Eli Lilly offers Emgality, a CGRP antagonist for migraine prevention, directly competing with Biohaven's rimegepant.
AMGEN
AMGN
Mkt Cap187.56B
Amgen's Aimovig, a CGRP receptor blocker for migraine prevention, competes with Biohaven's migraine portfolio.
Teva- Pharmaceutical Industries
TEVA
Mkt Cap35.03B
Teva Pharmaceutical's Ajovy, a migraine prevention medication, competes in the same space as Biohaven's treatments.
Novartis
NVS
Mkt Cap297.32B
Novartis, in collaboration with Amgen, markets Aimovig, competing in the migraine prevention market against Biohaven.
Pfizer
PFE
Mkt Cap161.09B
Pfizer competes in various therapeutic areas including CNS disorders, which could put it in competition with Biohaven's neurological focus.
Abbvie
ABBV
Mkt Cap369.39B
AbbVie, through its acquisition of Allergan, competes in the migraine market, particularly with Botox and Ubrelvy, a direct competitor to Biohaven's products.
Merck
MRK
Mkt Cap298.84B
Merck competes in the broader pharmaceutical market, including treatments for conditions that Biohaven targets, potentially competing in future neurological or migraine treatments.
Johnson & Johnson
JNJ
Mkt Cap585.7B
Johnson & Johnson, through its pharmaceutical division Janssen, competes in the neuroscience area, including treatments for migraines and other CNS disorders.
GSK
GSK
Mkt Cap113.29B
GlaxoSmithKline offers products for CNS disorders, including migraine treatments, potentially competing with Biohaven's migraine portfolio.

About

Biohaven Ltd. is a clinical-stage biopharmaceutical company. The Company focuses on development of therapies for neurological and immunoscience diseases that can change current treatment paradigms.
Show more...
CEO
ISIN
VGG1110E1079

Listings

XNYS
US
BHVN
SA
BR
BHVN34.SA
BOATS
BOATS
BHVN.BOATS

0 Comments

Share your thoughts

FAQ

What is Biohaven stock price today?▼
The current price of BHVN.BOATS is $9.8 USD — it has increased by +3.38% in the past 24 hours. Watch Biohaven stock price performance more closely on the chart.
What is Biohaven stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Biohaven stocks are traded under the ticker BHVN.BOATS.
What is Biohaven market cap?▼
Today Biohaven has the market capitalization of 1.47B
When is the next Biohaven earnings date?▼
Biohaven is going to release the next earnings report on May 08, 2026.
What were Biohaven earnings last quarter?▼
BHVN.BOATS earnings for the last quarter are -1.21 USD per share, whereas the estimation was -1.19 USD resulting in a -1.85% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Biohaven revenue for the last year?▼
Biohaven revenue for the last year amounts to 0 USD.
What is Biohaven net income for the last year?▼
BHVN.BOATS net income for the last year is -1.69B USD.
When did Biohaven complete a stock split?▼
Biohaven has not had any recent stock splits.